验证数据展示
经过测试的应用
| Positive IF/ICC detected in | A549 cells |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
CL488-67166 targets ACLY in IF/ICC applications and shows reactivity with Human, Mouse, Rat samples.
| 经测试应用 | IF/ICC Application Description |
| 经测试反应性 | Human, Mouse, Rat |
| 免疫原 | ACLY fusion protein Ag7709 种属同源性预测 |
| 宿主/亚型 | Mouse / IgM |
| 抗体类别 | Monoclonal |
| 产品类型 | Antibody |
| 全称 | ATP citrate lyase |
| 别名 | ACL, ACLY, ATP citrate (pro S ) lyase, ATP citrate lyase, ATP citrate synthase, ATPCL, Citrate cleavage enzyme, CLATP |
| 计算分子量 | 121 kDa |
| 观测分子量 | 120 kDa |
| GenBank蛋白编号 | BC006195 |
| 基因名称 | ACLY |
| Gene ID (NCBI) | 47 |
| RRID | AB_2934524 |
| 偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
| 最大激发/发射波长 | 493 nm / 522 nm |
| 形式 | Liquid |
| 纯化方式 | Caprylic acid/ammonium sulfate precipitation |
| UNIPROT ID | P53396 |
| 储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
| 储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
ACLY(ATP-citrate synthase) is also named as ACL. It is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA. ACLY serves as not only a target in oxygenated cells for suppression of lipid synthesis and histone acetylation, but also as a susceptible target in hypoxic cells to restore inhibition of glycolysis. In nonsmall cell lung carcinoma and hepatocellular carcinoma, ACLY is overexpressed compared with normal parenchyma suggesting that ACLY may represent a common target among highly malignant tumors(PMID:19795461). This protein has 2 isoforms produced by alternative splicing.
实验方案
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 488 ACLY antibody CL488-67166 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |